Bank of America’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-26,739
| Closed | -$4K | – | 7558 |
|
|
2019
Q4 | $4K | Buy |
26,739
+25,739
| +2,574% | +$3.51K | ﹤0.01% | 6821 |
|
|
2019
Q3 | $0 | Sell |
1,000
-3,365
| -77% | -$607 | ﹤0.01% | 7671 |
|
|
2019
Q2 | $1K | Buy |
4,365
+3,365
| +337% | +$681 | ﹤0.01% | 7121 |
|
|
2019
Q1 | $0 | Hold |
1,000
| – | – | ﹤0.01% | 7593 |
|
|
2018
Q4 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 7037 |
|
|
2018
Q3 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 7194 |
|
|
2018
Q2 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 7021 |
|
|
2018
Q1 | $2K | Hold |
1,000
| – | – | ﹤0.01% | 6929 |
|
|
2017
Q4 | $1K | Sell |
1,000
-911
| -48% | -$1.24K | ﹤0.01% | 6961 |
|
|
2017
Q3 | $2K | Sell |
1,911
-7,519
| -80% | -$9.61K | ﹤0.01% | 6895 |
|
|
2017
Q2 | $13K | Buy |
9,430
+2,615
| +38% | +$3.78K | ﹤0.01% | 6364 |
|
|
2017
Q1 | $13K | Buy |
6,815
+1,031
| +18% | +$4.66K | ﹤0.01% | 6475 |
|
|
2016
Q4 | $30K | Buy |
5,784
+3,574
| +162% | +$18.8K | ﹤0.01% | 6170 |
|
|
2016
Q3 | $12K | Sell |
2,210
-731
| -25% | -$4.17K | ﹤0.01% | 6338 |
|
|
2016
Q2 | $16K | Buy |
2,941
+1,941
| +194% | +$10.2K | ﹤0.01% | 6344 |
|
|
2016
Q1 | $4K | Sell |
1,000
-2,537
| -72% | -$10.4K | ﹤0.01% | 6665 |
|
|
2015
Q4 | $21K | Buy |
3,537
+3,324
| +1,561% | +$22.6K | ﹤0.01% | 6409 |
|
|
2015
Q3 | $2K | Sell |
213
-247
| -54% | -$1.92K | ﹤0.01% | 6997 |
|
|
2015
Q2 | $3K | Buy |
+460
| New | +$3.56K | ﹤0.01% | 6993 |
|
|
2014
Q1 | – | Sell |
-51
| Closed | – | – | 8250 |
|
|
2013
Q4 | $0 | Buy |
+51
| New | +$334 | ﹤0.01% | 8265 |
|
|
2013
Q3 | – | Sell |
-108
| Closed | – | – | 8120 |
|
|
2013
Q2 | $0 | Buy |
+108
| New | +$443 | ﹤0.01% | 7810 |
|
Bank of America's GNMX Position: Q1 2020 in Review
Bank of America sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 26,739 shares — an estimated $4K sold.
Bank of America first reported a position in GNMX in Q2 2013 and held it in 21 quarters. The position peaked at $30K in Q4 2016. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Bank of America reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Bank of America sold 26,739 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $4K.
- Bank of America first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 21 quarters.
- Bank of America's Aevi Genomic Medicine Inc position peaked at $30K in Q4 2016.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Bank of America's 13F filing for Q1 2020, filed 15 May 2020.